1
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A “Window of Opportunity” Pilot Study.
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:January 12, 2024Recruiting
Include Studies Not Open or Pending
Condition(s):Head and Neck Squamous Cell CarcinomaLast Updated:January 12, 2024Recruiting
Condition(s):Chronic Widespread PainLast Updated:November 8, 2023Recruiting
At TrialBulletin.com, we keep tabs on over 200,000 clinical trials in the US and abroad, using medical data supplied directly by the US National Institutes of Health. Please see the About and Contact page for details.